Journal of hepatology

Journal of hepatology
Audio Summaries

Every issue of Journal of hepatology moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

103 audio summariesNLM Catalog

Specialties

Journal of hepatology covers research in these specialties.

Recent summaries

The latest articles summarized from Journal of hepatology.

Checkpoint Inhibition during primary hepatitis E virus infection alters memory development of virus-specific T-cells in humans.

Nov 19, 2026

This study asks how PD-1 blockade during a primary hepatitis E virus (HEV) infection shapes the expansion and memory fate of de novo virus-specific CD8+ T-cells in humans. Comparing patients receiving immune checkpoint inhibitors with untreated patients, the authors found that treated patients' HEV-specific CD8+ T-cells showed enhanced expansion, cytotoxicity, and terminal differentiation, retaining a cytotoxic program and long-lived effector-like features rather than forming classical memory subsets. Although these cells persisted for over two years, their functional recall responses were diminished, suggesting PD-1 signaling during primary priming regulates antiviral CD8+ T-cell memory fate with implications for viral infection, vaccination, and immunotherapy.

Translocation of the environmental bacterium Aquitalea magnusonii promotes systemic inflammation and liver fibrosis in chronic liver disease.

Nov 13, 2026

This study asks whether non-commensal environmental bacteria, using *Aquitalea magnusonii* as a model, can cross the intestinal barrier and drive liver inflammation and fibrosis in chronic liver disease. Using patient samples, human intestinal and immune cell models, and alcohol-related and metabolic liver disease mouse models, the authors found that *A. magnusonii* translocates to the liver, produces ACLF-associated metabolites and virulence-enriched outer membrane vesicles, and activates TLR2/TLR4 signaling. Exposure to the bacterium or its molecular patterns increased inflammation and fibrosis in vitro and in vivo, suggesting a previously underappreciated environmental contribution to liver disease progression.

Senescence induces clonal failure of hepatocyte plasticity and reshapes regenerative lineages.

Nov 10, 2026

Telomere dysfunction is a known driver of cellular senescence and chronic liver disease, but how physiological, resolvable telomere damage affects liver regeneration has been unclear. Using an AAV-CRISPR system to induce telomeric breaks in mouse hepatocytes, the authors found that senescence did not substantially impair hepatocyte survival or basal metabolism, but instead blocked hepatocyte-to-ductal metaplasia during chronic injury, skewing clonal composition and worsening the ductular reaction. Human cirrhotic data linked preserved telomere integrity to bipotent hepatocyte states, and an in vivo CRISPR screen identified regulators of hepatocyte dedifferentiation under telomere stress, positioning senescence as a constraint on hepatocyte plasticity rather than a direct cause of hepatocyte loss.

Seladelpar for alkaline phosphatase normalization in primary biliary cholangitis: The IDEAL phase III randomized controlled trial.

Nov 8, 2026

Seladelpar, a selective PPAR-delta agonist, was tested in a phase III randomized, double-blind trial to determine whether it can normalize alkaline phosphatase (ALP) in patients with primary biliary cholangitis whose ALP is above normal but below 1.67× the upper limit of normal despite ursodeoxycholic acid (UDCA) therapy or UDCA intolerance. At Month 12, ALP normalization (≤ULN with at least a 15% decrease) occurred in 75.4% of seladelpar-treated patients versus 16.1% on placebo, with similar adverse event rates and fewer serious adverse events. These results suggest seladelpar can achieve biochemical normalization in this lower-threshold group, which may inform treatment goals for patients at higher risk of progression.

Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo Base Editing in a Patient with Alpha-1 Antitrypsin Deficiency.

Nov 2, 2026

This case report describes the first clinical assessment of in vivo base editing for alpha-1 antitrypsin deficiency (PI*ZZ genotype), asking whether the therapy can directly correct the SERPINA1 mutation in the liver. A liver biopsy taken 10 weeks after treatment in a 66-year-old patient showed about 54-57% correction of PI*ZZ alleles, with no detectable bystander or off-target editing, no hepatic inflammation, and transient transaminase elevation that resolved. Sustained circulating levels of biologically active AAT over follow-up support the feasibility of this approach, though findings come from a single patient.

Crosstalk along the gut-liver axis in liver disease: Clinical and mechanistic aspects.

Oct 28, 2026

This review examines the bidirectional communication between the gut and liver, asking how gut-derived factors (such as intestinal permeability, microbiota composition, and immune signaling) drive or modify liver disease, and how liver-derived factors like bile acids reciprocally shape intestinal ecology and immunity. Using autoimmune, metabolic, and toxic hepatobiliary disorders as model conditions, the authors synthesize recent mechanistic and clinical evidence and discuss implications for disease stratification, prevention, and therapy. They conclude by identifying key knowledge gaps and priorities for future research.

Intestinal Candida albicans promotes HCC progression and anti-PD-1 resistance via IL-17A and Trem2+ macrophages.

Oct 26, 2026

This study asks whether intestinal fungal dysbiosis, specifically Candida albicans, drives hepatocellular carcinoma progression and resistance to immune checkpoint inhibitors. In patients, higher fecal C. albicans was linked to advanced disease, shorter survival, and reduced benefit from ICI therapy, and in mouse models C. albicans gavage promoted tumor growth via an IL-17A-driven circuit that recruits and polarizes immunosuppressive Trem2+ macrophages, suppressing CD8+ T cells. Antifungal treatment and IL-17A blockade attenuated tumor progression and partially restored anti-PD-1 efficacy, suggesting fecal C. albicans and this immune axis may be candidate biomarkers and therapeutic targets, though the human cohorts were modest and the antifungal approach was only tested in mice.

Abnormal left ventricular mass as a prognostic marker for outcomes in infants and children with cirrhosis.

Oct 12, 2026

This study investigated whether myocardial changes, specifically left ventricular mass, characterize cirrhotic cardiomyopathy in children and can predict adverse outcomes. Comparing 226 children with cirrhosis listed for liver transplant against 160 non-cirrhotic controls, the authors found higher LV mass in the cirrhotic group, and left ventricular mass index (LVMI) values of roughly 88 to 95 g/m^2.7 were independently associated with waitlist decompensation, serious post-transplant adverse events, and mortality. Adding LVMI to PELD-Cr/MELD improved discrimination for waitlist decompensation and serious adverse events, suggesting it may enhance risk stratification for liver transplant allocation.

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study.

Oct 6, 2026

The SIERRA phase IIIb study asked whether the first-line dual immunotherapy regimen STRIDE (single tremelimumab plus regular durvalumab) can be given safely and effectively to patients with unresectable hepatocellular carcinoma who are typically excluded from phase III trials, namely those with Child-Pugh B7/B8 liver function, ECOG performance status 2, or main portal vein thrombosis (Vp4). In 111 participants, the rate of Grade 3/4 treatment-related adverse events within 6 months was 19.8%, and the objective response rate was 14.4% (6.8% in Child-Pugh B7/B8, 21.3% in ECOG PS 2, and 15.0% in Vp4). The authors conclude that STRIDE offers a favourable risk-benefit profile in this underrepresented, high-need population.

Temporal assessment of spatial and single-cell transcriptomes identifies CD226-NECTIN2 T cell-cholangiocyte interaction in bile duct inflammation.

Oct 5, 2026

This study used spatial and single-cell transcriptomics of livers from NOD.c3c4 mice (a model of bile duct inflammation) at multiple ages, combined with cell-interaction analysis, to identify how immune cells and cholangiocytes communicate in disease. The authors asked which T cell-cholangiocyte interactions drive biliary inflammation, and identified CD226-NECTIN2 as a candidate; knocking down Nectin2 in vitro and blocking CD226 in mice reduced T cell activation. CD226-NECTIN2 co-localization at inflamed bile ducts in PSC, PBC, and alcohol-related liver disease explants suggests it may be a future therapeutic target.

Listen to Journal of hepatology

14-day free trial. Every new article, summarized in ~3 minutes.